Background
Jalali was born on May 16, 1962 in Tehran, Iran.
Boston, Massachusetts, United States
University of Massachusetts
Boston, Massachusetts, United States
Northeastern University
San Francisco, California, United States
San Francisco State University
New York City, New York, United States
Forest Laboratories, Inc.
San Diego, California, United States
Neurocrine Biosciences
San Diego, California, United States
Thermo Fisher Scientific, Inc.
Jalali was born on May 16, 1962 in Tehran, Iran.
Jalali received a Bachelor of Science degree from the University of Massachusetts in 1983. Five years later he earned his Doctor of Philosophy degree from Northeastern University.
Jalali began his career as a postdoctoral research fellow at San Francisco State University in 1988 and held it for two years. In 1991, he took a position of a manager in metabolism at Pharmacology and Toxicology Research Laboratory. Then in 1998, Kayvon was appointed a research scientist at Forest Laboratories, Inc.
Also he served as a group leader at Ribozyme Pharmaceuticals, Inc. from 2000 to 2002. There Kayvon led a group of scientists working on determining the DMPK properties of synthetic oligonucleotides (Ribozymes) with pharmaceutical properties. Also in 2002, he became a bioanalytical services manager at In Vitro Technologies, where he managed a bioanalytical services group responsible for providing bioanalytical support for internal producy development projects, as well as providing in vitro metabolism services to pharmaceutical companies on a contract basis.
In 2004, he held a position of an associate director of preclinical development department at Neurocrine Biosciences, where he worked until 2009. There Jalali was responsible for leading a group of scientists working on ADME studies in support of discovery and development of compounds aimed at neurology and endocrinology targets. Since 2010 he has been a field applications scientist at Thermo Fisher Scientific, Inc. In addition, since 2018 Kayvon has served as a technical sales representative at the same company.
Jalali developed and validated bioanalytical methods for bioequivalence and drug-drug interaction (DDI) clinical studies.
Also he developed ELISA (enzyme-linked immunosorbent assay) and LC-MS (liquid chromatography-tandem mass spectrometry) assyas for determination of Ribozyme levels in preclinical and clinical samples.
Jalali is a member of American Chemical Society. He was a chairman of Iranian chemists' association from 2000 to 2002.
Jalali is married.